Prevention and treatment of coronary distal embolization in the setting of acute myocardial infarction: Pharmacologic approach

Current Vascular Pharmacology

Volumn 10, Issue 4, 2012, Pages 463-467

  de Caterina, Alberto R ^a,b   Porto, Italo ^a   de Maria, Giovanni Luigi ^a   Banning, Adrian P ^b  

^a CATHOLIC UNIVERSITY   (Italy)

^b OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Adenosine; Distal embolization; GP IIb IIIa inhibitors; Nitroprusside; ST elevation myocardial infarction

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE; C REACTIVE PROTEIN; CALCIUM ANTAGONIST; CLOPIDOGREL; CREATINE KINASE MB; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRIC OXIDE SYNTHASE; NITROPRUSSIDE SODIUM; VERAPAMIL;

ACUTE HEART INFARCTION; ANGIOGRAPHY; ATHEROSCLEROTIC PLAQUE; CORONARY ARTERY BLOOD FLOW; DISTAL EMBOLIZATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; EMBOLISM; ENZYME ACTIVITY; HEART INFARCTION SIZE; HEART MUSCLE CONTRACTILITY; HEART PROTECTION; HUMAN; HYPEREMIA; INFLAMMATION; INTRAVASCULAR ULTRASOUND; META ANALYSIS (TOPIC); MICROCIRCULATION; MORTALITY; PATHOPHYSIOLOGY; PERCUTANEOUS CORONARY INTERVENTION; PLEIOTROPY; REPERFUSION; REVIEW; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THROMBOSIS; VASCULAR SMOOTH MUSCLE;

ANTI-INFLAMMATORY AGENTS; ARRHYTHMIAS, CARDIAC; CORONARY VESSELS; EMBOLISM; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MICROVESSELS; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; VASODILATOR AGENTS;

EID: 84861709375     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/157016112800812809     Document Type: Review

References (58)

1. Davies MJ, Thomas AC. Plaque fissuring: the cause of acute myocardial infarction, sudden ischaemic death, and crescendo angina. Br Heart J 1985; 53: 363-73.
2. Falk E. Unstable angina with fatal outcome: dynamic coronary thrombosis leading to infarction and/or sudden death: autopsy evidence of recurrent mural thrombosis with peripheral embolization culminating in total vascular occlusion. Circulation 1985; 71: 699-708.
3. Davies MJ, Thomas AC, Knapman PA, Hangartner JR. Intramyocardial platelet aggregation in patients with unstable angina suffering sudden ischemic cardiac death. Circulation 1986; 73: 418-27.
4. Frink RJ, Rooney PA, Trowbridge JO, Rose JP. Coronary thrombosis and platelet/fibrin microemboli in death associated with acute myocardial infarction. Br Heart J 1988; 59: 196-200.
5. Erbel R, Heusch G. Brief review: coronary microembolization. J Am Coll Cardiol 2000; 36: 22-4.
6. Topol EJ, Yadav JS. Recognition of the importance of embolization in atherosclerotic vascular disease. Circulation 2000; 101: 570-80.
7. Good CW, Blankenship JC, Scott TD, Skelding KA, Berger PB, Wood GC. Feasibility and safety of ad hoc percutaneous coronary intervention in the modern era. J Invasive Cardiol 2009; 21: 194-200.
8. Mattichak SJ, Dixon SR, Shannon F, Boura JA, Safian RD. Failed percutaneous coronary intervention: a decade of experience in 21,000 patients. Catheter Cardiovasc Interv 2008; 71: 131-7.
9. Califf RM, Abdelmeguid AE, Kuntz RE, et al. Myonecrosis after revascularization procedures. J Am Coll Cardiol 1998; 31: 241e51.
10. Kelly RV, Cohen MG, Stouffer GA. Mechanical thrombectomy options in complex percutaneous coronary interventions. Catheter Cardiovasc Interv 2006; 68: 917-28.
11. El-Jack SS, Suwatchai P, Stewart JT, et al. Distal embolization during native vessel and vein graft coronary intervention with a vascular protection device: predictors of high-risk lesions. J Interv Cardiol 2007; 20: 474-80.
12. Quan V-H, Huynh R, Seifert PA, et al. Morphometric analysis of particulate debris extracted by four different embolic protection devices from coronary arteries, aortocoronary saphenous vein conduits, and carotid arteries. Am J Cardiol 2005; 95: 1415-9.
13. Steigen SE, Steigen TK, Gunnes P, et al. Histopathology of material captured by embolic protection device after percutaneous coronary interventions in atherosclerotic saphenous vein grafts. Euro-Intervention 2006; 2: 244-9.
14. Popma JJ, Cox N, Hauptmann KE, et al. Initial clinical experience with distal protection using the FilterWire in patients undergoing coronary artery and saphenous vein graft percutaneous intervention. Catheter Cardiovasc Interv 2002; 57: 125-34.
15. Virmani R, Burke AP, Farb A, Kolodgie FD. Pathology of the vulnerable plaque. J Am Coll Cardiol 2006; 47: C13-C18.
16. Hong YJ, Jeong MH, Choi YH, et al. Impact of plaque components on no-reflow phenomenon after stent deployment in patients with acute coronary syndrome: a virtual histology-intravascular ultrasound analysis. Eur Heart J 2011; 32: 2059-66.
17. Yip HK, Chen MC, Chang HW, et al. Angiographic morphologic features of infarct-related arteries and timely reperfusion in acute myocardial infarction: predictors of slow-flow and no-reflow phenomenon. Chest 2002; 122: 1322-32.
18. Taylor AJ, Bobik A, Berndt MC, Ramsay D, Jennings G. Experimental rupture of atherosclerotic lesions increases distal vascular resistance: a limiting factor to the success of infarct angioplasty. Arterioscler Thromb Vasc Biol 2002; 22: 153-60.
19. Leineweber K, Böse D, Vogelsang M, Haude M, Erbel R, Heusch G. Intense vasoconstriction in response to aspirate from stented saphenous vein aortocoronary bypass grafts. J Am Coll Cardiol 2006; 47: 981-6.
20. Charron T, Jaffe R, Segev A, et al. Effects of distal embolization on the timing of platelet and inflammatory cell activation in interventional coronary no-reflow. Thromb Res 2010; 126: 50-5.
21. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 2: 349-60.
22. Patti G, Colonna G, Pasceri V, Pepe LL, Montinaro A, Di Sciascio G. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study. Circulation 2005; 111: 2099-106.
23. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Clopidogrel withdrawal is associated with proinflammatory and prothrombotic effects in patients with diabetes and coronary artery disease. Diabetes 2006; 55: 780-4.
24. Warnholtz A, Ostad MA, Velich N, et al. A single loading dose of clopidogrel causes dose-dependent improvement of endothelial dysfunction in patients with stable coronary artery disease: results of a double-blind, randomized study. Atherosclerosis 2008; 196: 689-95.
25. Patti G, Grieco D, Dicuonzo G, Pasceri V, Nusca A, Di Ssciascio G. High vs. standard clopidogrel maintenance dose after percutaneous coronary intervention and effects on platelet inhibition, endothelial function, and inflammation. J Am Coll Cardiol 2011; 57: 771-8.
26. Wiviott SD, Braunwald E, McCabe CH; TRITON-TIMI 38 Investigators. Prasugrel vs. clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-15.
27. Wallentin L, Becker RC, Budaj A, et al.; PLATO Investigators. Ticagrelor vs. clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045-57.
28. The PRISM-PLUS investigators. The platelet receptor inhibition in ischemic syndrome management in patients limited by unstable signs and symptoms (PRISM-PLUS). N Engl J Med 1998; 338: 1488-97.
29. Gibson CM, de Lemos JA, Murphy SA, et al. Combination therapy with abciximab reduces angiographically evident thrombus in acute myocardial infarction: a TIMI 14 substudy. Circulation 2001; 103: 2550-4.
30. Ellis SG, Lincoff MA, Miller D, et al. Reduction in complications of angioplasty with abciximab occurs largely independently of baseline lesion morphology. J Am Coll Cardiol 1998; 32: 1619-23.
31. Collet JP, Montalescot G, Lesty C, et al. Effect of abciximab on the architecture of platelet-rich clots in patients with acute myocardial infarction undergoing primary coronary intervention. Circulation 2001; 103: 2328-31.
32. Naimushin YA, Mazurov AV. Role of glycoprotein IIb-IIIa (alpha IIb beta 3-integrin) in stimulation of secretion from platelet granules. Biochemistry 2003; 68: 209-16.
33. Bellandi F, Maioli M, Gallopin M, Toso A, Dabizzi RP. Increase of myocardial salvage and left ventricular function recovery with intracoronary abciximab downstream of the coronary occlusion in patients with acute myocardial infarction treated with primary coronary intervention. Catheter Cardiovasc Interv 2004; 62: 186-92.
34. Gu YL, Kampinga MA, Wieringa WG, Intracoronary vs. intravenous administration of abciximab in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with thrombus aspiration: the comparison of intracoronary vs. intravenous abciximab administration during emergency reperfusion of ST-segment elevation myocardial infarction (CICERO) trial. Circulation 2010; 122: 2709-17.
35. Angeja BG, Gunda M, Murphy SA, et al. TIMI myocardial perfusion grade and ST segment resolution: association with infarct size as assessed by single photon emission computed tomography imaging. Circulation 2002; 105: 282-5.
36. Niccoli G, Burzotta F, Galiuto L, Crea F. Myocardial no-reflow in humans. J Am Coll Cardiol 2009; 54: 281-92.
37. Mulukutla SR, Marroquin OC, Smith C, et al. Effect of statin therapy prior to elective percutaneous coronary intervention on frequency of periprocedural myocardial injury. Am J Cardiol 2004; 94: 1363-6.
38. Pasceri V, Patti G, Nusca A, Pristipino C, Richichi G, Di Sciascio G; ARMYDA Invesitgators. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study. Circulation 2004; 110: 674-8.
39. Patti G, Cannon CP, Murphy SA, et al. Clinical benefit of statin pretreatment in patients undergoing percutaneous coronary intervention: a collaborative patient-level meta-analysis of 13 randomized studies. Circulation 2011; 123: 1622-32.
40. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study. A randomized controlled trial. JAMA 2001; 285: 1711-8.
41. Gibson CM, Pride YB, Hochberg CP, Sloan S, Sabatine MS, Cannon CP; TIMI Study Group. Effect of intensive statin therapy on clinical outcomes among patients undergoing percutaneous coronary intervention for acute coronary syndrome. PCI-PROVE IT: A PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) Substudy. J Am Coll Cardiol 2009; 54: 2290-5.
42. Mentzer RM Jr, Bunger R, Lasley RD. Adenosine enhanced preservation of myocardial function and energetics. Possible involvement of the adenosine A1 receptor system. Cardiovasc Res 1993; 27: 28-35.
43. Zhou Z, Bunger R, Lasley RD, Hegge JO, Mentzer RM Jr. Adenosine pretreatment increases cytosolic phosphorylation potential and attenuates postischemic cardiac dysfunction in swine. Surg Forum 1993; 64: 249-52.
44. Mauser M, Hoffmeister HM, Nienaber C, Schaper W. Influence of ribose, adenosine and "AICAR" on the rate of myocardial adenosine triphosphate synthesis during reperfusion after coronary artery occlusion in the dog. Circ Res 1985; 56: 220-30.
45. Ely SW, Berne RM. Protective effects of adenosine in myocardial ischemia. Circulation 1992; 85: 893-904.
46. Cronstein BN, Kramer SB, Weissmann G, Hirschhorn R. Adenosine: physiologic modulator of superoxide anion generation by human neutrophils. J Exp Med 1983; 158: 1160-77.
47. Russo I, Doronzo G, Mattiello L, De Salve A, Trovati M, Anfossi G. The activity of constitutive nitric oxide synthase is increased by the pathway cAMP/cAMP-activated protein kinase in human platelets. New insights into the antiaggregating effects of cAMPelevating agents. Thromb Res 2004; 114: 265-73.
48. Jordan JE, Zhao ZQ, Sato H, Taft S, Vinten-Johansen J. Adenosine A2 receptor activation attenuates reperfusion injury by inhibiting neutrophil accumulation, superoxide generation and coronary endothelial adherence. J Pharmacol Exp Ther 1997; 280: 301-9.
49. Cronstein BN, Levin RI, Belanoff J, Weismann G, Hirschhorn R. Adenosine: an endogenous inhibitor of neutrophil-mediated injury to endothelial cells. J Clin Invest 1986; 78: 760-70.
50. Marzilli M, Orsini E, Marraccini P, Testa R. Beneficial effects of intracoronary adenosine as an adjunct to primary angioplasty in acute myocardial infarction. Circulation 2000;101:2154-9.
51. Mahaffey KW, Puma JA, Barbagelata A, et al. Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction. Results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trial. J Am Coll Cardiol 1999; 34: 1711-20.
52. Ross AM, Gibbons RJ, Stone GW, Kloner RA, Alexander RW. A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II). J Am Coll Cardiol 2005; 45: 1775-80.
53. Desmet W, Bogaert J, Dubois C, et al. High-dose intracoronary adenosine for myocardial salvage in patients with acute STsegment elevation myocardial infarction. Eur Heart J 2011; 32: 867-77.
54. Bates JN, Baker MT, Guerra R Jr, Harrison DG. Nitric oxide generation from nitroprusside by vascular tissue: evidence that reduction of the nitroprusside ion and cyanide loss are required. Biochem Pharmacol 1991; 42: S157-S165.
55. Parham WA, Bouhasin A, Ciaramita JP, Khoukaz S, Herrmann SC, Kern MJ. Coronary hyperemic dose responses of intracoronary sodium nitroprusside. Circulation 2004; 109: 1236-43.
56. Niccoli G, D'amario D, Spaziani C, et al. Randomized evaluation of intracoronary nitroprusside vs. adenosine after thrombus aspiration during primary percutaneous coronary intervention for the prevention of no-reflow in acute myocardial infarction: the REOPENAMI study protocol. J Cardiovasc Med 2009; 10: 585-92.
57. Piana RN, Paik GY, Moscucci M, et al. Incidence and treatment of 'no-reflow' after percutaneous coronary intervention. Circulation 1994; 89: 2514-8.
58. Taniyama Y, Ito H, Iwakura K, et al. Beneficial effect of intracoronary verapamil on microvascular and myocardial salvage in patients with acute myocardial infarction. J Am Coll Cardiol 1997; 30: 1193-9.